drugset / Trial / NCT04864444

Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities

NCT04864444

RandomizedParallel-groupOpen-labelPrevention

Summary

This community-based cluster randomized controlled trial aims to evaluate the effectiveness of time-limited, community-wide mass drug administration (MDA) with dihydroartemisinin-piperaquine (DHA-PPQ) and single low-dose primaquine (SLD-PQ) on Plasmodium falciparum transmission compared to standard-of-care seasonal malaria chemoprevention (SMC). The study will be conducted in a moderate-to-low malaria transmission setting of Senegal with optimized malaria control measures (e.g., proactive community case management and piperonyl butoxide pyrethroid long-lasting insecticidal nets (PBO LLINS)).

Timeline

Start
2021-06-19
Primary completion
2022-12-31
Completion
2023-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ARTENIMOL Small molecule 160 mg Oral
Subject ARTENIMOL Small molecule 320 mg Oral
Subject Primaquine Small molecule
Subject piperaquine Small molecule 20 mg Oral
Subject piperaquine Small molecule 40 mg Oral